Johnson & Johnson Submits Applications in the U.S. and EU Seeking Approval of Darzalex Fasporo or Darzalex as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma
November 09, 2024
November 09, 2024
NEW BRUNSWICK, New Jersey, Nov. 9 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
If approved, DARZALEX FASPRO will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end organ damage
* * *
RARITAN, N.J., November 8, 2024 - Johnson & Johnson (NYSE:JNJ) . . .
* * *
If approved, DARZALEX FASPRO will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end organ damage
* * *
RARITAN, N.J., November 8, 2024 - Johnson & Johnson (NYSE:JNJ) . . .